Characterization of bone only metastasis patients with respect to tumor subtypes

Metastatic breast cancer (MBC) patients with bone only metastasis (BOM) are a unique population with limited characterization. We identified patients followed at MD Anderson Cancer Center from 01/01/1997 to 12/31/2015 for at least 6 months with a BOM diagnosis as first site of metastasis. Tumor subt...

Full description

Saved in:
Bibliographic Details
Published in:NPJ breast cancer 2018-01, Vol.4 (1), p.2-7, Article 2
Main Authors: Parkes, Amanda, Clifton, Katherine, Al-Awadhi, Aydah, Oke, Oluchi, Warneke, Carla L., Litton, Jennifer K., Hortobagyi, Gabriel N.
Format: Article
Language:English
Subjects:
631/67/1347
631/67/322
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer Research
Cell Biology
Estrogens
Human Genetics
Mammography
Medical diagnosis
Metastasis
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic breast cancer (MBC) patients with bone only metastasis (BOM) are a unique population with limited characterization. We identified patients followed at MD Anderson Cancer Center from 01/01/1997 to 12/31/2015 for at least 6 months with a BOM diagnosis as first site of metastasis. Tumor subtype (TS) was assessed by initial breast biopsy immunohistochemistry using hormonal receptor (HR) and HER2 status, with four subtypes identified: HR+/HER2−, HR+/HER2+, HR−/HER2−, HR−/HER2+. HR+ was defined as estrogen receptor or progesterone receptor ≥1%. We identified 1445 patients with BOM, 1048 with TS data available. Among these patients, the majority were HR+/HER2− (78%). Median time from breast cancer diagnosis to first bone metastasis was 2.3 years (95% CI 2.1, 2.5) and varied significantly by TS, with longer time to distant disease in HR+/HER2− patients relative to all other TS ( p  
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-018-0054-x